Rosty Christophe, Ueki Takashi, Argani Pedram, Jansen Marnix, Yeo Charles J, Cameron John L, Hruban Ralph H, Goggins Michael
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205-2196, USA.
Am J Pathol. 2002 Jan;160(1):45-50. doi: 10.1016/S0002-9440(10)64347-7.
Using the National Center for Biotechnology Information Serial Analysis of Gene Expression database, we found that S100A4, a calcium-binding protein previously implicated in metastasis, was expressed in five of seven pancreatic carcinoma libraries but not in the two normal pancreatic duct libraries. We confirmed the overexpression of S100A4 using reverse transcriptase-polymerase chain reaction, which demonstrated that 18 of 19 (95%) pancreatic carcinoma cell lines expressed S100A4. Using immunohistochemistry, we found that 57 of 61 invasive pancreatic carcinomas (93%), 3 of 18 high-grade pancreatic intraepithelial neoplasia lesions (17%), and 0 of the 69 low-grade pancreatic intraepithelial neoplasia lesions expressed S100A4 protein, whereas normal pancreatic tissue and tissue affected by chronic pancreatitis did not label. Expression of S100A4 was associated with poor differentiation of the pancreatic adenocarcinomas (P = 0.001). We found that three CpG sites in the first intron of the S100A4 gene were approximately 90% methylated in microdissected normal pancreatic duct cells using bisulfite-modified sequencing and in two cell lines and three primary pancreatic carcinomas with a reduced or absent expression of S100A4. In contrast, these CpGs were 100% hypomethylated in 11 of 12 pancreatic cancer cell lines by methylation-specific polymerase chain reaction. The association between the expression of S100A4 and hypomethylation of the first intron of S100A4 was statistically significant (P = 0.002). These data suggest that the majority of pancreatic carcinomas undergo selection for hypomethylation and overexpression of S100A4. Because most pancreatic carcinomas express S100A4, it may be a useful target for early detection strategies.
利用美国国立生物技术信息中心的基因表达序列分析数据库,我们发现,S100A4(一种先前被认为与转移有关的钙结合蛋白)在7个胰腺癌文库中的5个中有表达,但在2个正常胰管文库中未表达。我们使用逆转录聚合酶链反应证实了S100A4的过表达,结果显示19个胰腺癌细胞系中有18个(95%)表达S100A4。通过免疫组织化学,我们发现61例浸润性胰腺癌中有57例(93%)、18例高级别胰腺上皮内瘤变病变中有3例(17%)、69例低级别胰腺上皮内瘤变病变中有0例表达S100A4蛋白,而正常胰腺组织和受慢性胰腺炎影响的组织未显示标记。S100A4的表达与胰腺腺癌的低分化相关(P = 0.001)。我们发现,使用亚硫酸氢盐修饰测序法,在显微切割的正常胰管细胞以及两个细胞系和三个S100A4表达降低或缺失的原发性胰腺癌中,S100A4基因第一内含子中的三个CpG位点甲基化程度约为90%。相比之下,通过甲基化特异性聚合酶链反应,在12个胰腺癌细胞系中的11个中,这些CpG位点的甲基化程度为100%。S100A4的表达与S100A4第一内含子的低甲基化之间的关联具有统计学意义(P = 0.002)。这些数据表明,大多数胰腺癌经历了S100A4低甲基化和过表达的选择过程。由于大多数胰腺癌表达S100A4,它可能是早期检测策略的一个有用靶点。